Provectus Biopharma (PVCT) to Offer Common Stocks and Warrants

August 24, 2016 4:06 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) announced that it intends to offer and sell shares of its Series B Convertible Preferred Stock and warrants to purchase common stock, subject to market and other conditions, in a "best efforts" public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.

Maxim Group LLC is acting as placement agent for the offering.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Equity Offerings

Related Entities

Maxim Group, S3

Add Your Comment